Q-omics provides the consensus-scored CNTNAP5 profile across patient tissues and cancer cell-line models. CNTNAP5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNTNAP5 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, CNTNAP5 RNA expression shows 15,315 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, KICH, and PCPG as cancer lineages where CNTNAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTNAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTNAP5 survival associations across molecular data types. CNTNAP5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTNAP5 RNA expression–survival associations across cancer types. High CNTNAP5 expression shows unfavorable associations in UVM, BLCA, THCA, CESC and LIHC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNTNAP5 RNA expression.
This table summarizes CNTNAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CNTNAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTNAP5 shows lower tumor expression in READ and higher tumor expression in KICH, LUSC, HNSC and LIHC. The KICH box plot shows higher CNTNAP5 RNA expression in tumor versus normal tissue (log2 FC = +3.059, t-test p < 0.001).
This table shows molecular features associated with CNTNAP5 in patient tissues and cancer cell lines. In patient samples, CNTNAP5 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, CNTNAP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
